These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7628828)

  • 1. Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats.
    Pham I; Lévy B; Fournié-Zaluski MC; Poitevin P; Roques BP; Michel JB
    Fundam Clin Pharmacol; 1995; 9(2):153-60. PubMed ID: 7628828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
    Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.
    Pham I; Gonzalez W; Doucet J; Fournie-Zaluski MC; Roques BP; Michel JB
    Eur J Pharmacol; 1996 Feb; 296(3):267-76. PubMed ID: 8904078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of long-term converting-enzyme inhibition in renal hypertensive rats.
    Salom MG; Salazar FJ; Fenoy FJ; Pinilla JM; Marín N; Quesada T
    Rev Esp Fisiol; 1990 Jun; 46(2):171-6. PubMed ID: 2274701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats.
    Wood JM; Mah SC; Schnell C
    J Cardiovasc Pharmacol; 1990; 16 Suppl 4():S60-4. PubMed ID: 1705630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
    Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats.
    Nelissen-Vrancken HJ; Struijker-Boudier HA; Smits JF
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):163-8. PubMed ID: 1376783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q; Larouche I; Schiffrin EL
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats.
    Yamamoto K; Chappell MC; Brosnihan KB; Ferrario CM
    Hypertension; 1992 Jun; 19(6 Pt 2):692-6. PubMed ID: 1317352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypotensive and hemodynamic effects of the new non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
    Shirota M; Iijima M; Ushijima T; Kajiwara Y; Kitabatake K
    Arzneimittelforschung; 1990 Dec; 40(12):1303-9. PubMed ID: 2095126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged inhibition of neutral endopeptidase 24.11 by sinorphan in stroke-prone spontaneously hypertensive rats.
    Stasch JP; Knorr A; Wegner M; Hirth-Dietrich C
    Hypertens Res; 1995 Jun; 18(2):137-43. PubMed ID: 7584920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
    Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
    J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats.
    Webb RL; Abramson ML; Beil ME; Odorico LM; Chatelain RE
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):632-42. PubMed ID: 9388046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats.
    Daull P; Lepage R; Benrezzak O; Cayer J; Beaudoin M; Belleville K; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    Drug Chem Toxicol; 2006; 29(2):183-202. PubMed ID: 16707327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
    Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular status following combined angiotensin-converting enzyme and AT1 receptor inhibition in conscious spontaneously hypertensive rats.
    Duke LM; Paull JR; Widdop RE
    Clin Exp Pharmacol Physiol; 2003; 30(5-6):317-23. PubMed ID: 12859420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.